Pacific Northwest Evidence-based Practice Center, Department of Medical Informatics and Clinical Epidemiology, Oregon Health & Science University, Portland.
Department of Family Medicine, Oregon Health & Science University, Portland.
JAMA. 2021 Sep 14;326(10):957-966. doi: 10.1001/jama.2021.10577.
The 2014 US Preventive Services Task Force (USPSTF) recommendation statement supported the effectiveness of screening for chlamydia and gonorrhea in asymptomatic, sexually active women 24 years or younger and in older women at increased risk for infection, although evidence for screening in men was insufficient.
To update the 2014 USPSTF review on screening for chlamydial and gonococcal infection in adults and adolescents, including those who are pregnant.
Cochrane Central Register of Controlled Trials, Cochrane Database of Systematic Reviews, and Ovid MEDLINE (January 1, 2014, through May 28, 2020) with surveillance through May 21, 2021.
Randomized clinical trials and observational studies of screening effectiveness, accuracy of risk stratification and alternative screening methods, accuracy of tests, and screening harms.
One investigator abstracted data; a second checked accuracy. Two investigators independently assessed study quality.
Complications of infection; infection transmission or acquisition; diagnostic accuracy of anatomical site-specific testing and collection methods; screening harms.
Twenty-seven studies were included (N = 179 515). Chlamydia screening compared with no screening was significantly associated with reduced risk of pelvic inflammatory disease (PID) in 2 of 4 trials and with reduced hospital-diagnosed PID (0.24% vs 0.38%); relative risk, 0.6 [95% CI, 0.4-1.0]), but not clinic-diagnosed PID or epididymitis, in the largest trial. In studies of risk prediction instruments in asymptomatic women, age younger than 22 years demonstrated comparable accuracy to extensive criteria. Sensitivity of chlamydial testing was similar at endocervical (89%-100%) and self- and clinician-collected vaginal (90%-100%) sites for women and at meatal (100%), urethral (99%), and rectal (92%) sites for men but lower at pharyngeal sites (69.2%) for men who have sex with men. Sensitivity of gonococcal testing was 89% or greater for all anatomical samples. False-positive and false-negative testing rates were low across anatomical sites and collection methods.
Screening for chlamydial infection was significantly associated with a lower risk of PID in young women. Risk prediction criteria demonstrated limited accuracy beyond age. Testing for asymptomatic chlamydial and gonococcal infections was highly accurate at most anatomical sites, including urine and self-collected specimens. Effectiveness of screening in men and during pregnancy, optimal screening intervals, and adverse effects of screening require further evaluation.
2014 年美国预防服务工作组(USPSTF)的推荐声明支持对 24 岁及以下无症状、有性行为的女性和感染风险增加的老年女性进行衣原体和淋病筛查,尽管男性筛查的证据不足。
更新 2014 年 USPSTF 对成人和青少年衣原体和淋病感染筛查的审查,包括孕妇。
Cochrane 对照试验中心注册库、Cochrane 系统评价数据库和 Ovid MEDLINE(2014 年 1 月 1 日至 2020 年 5 月 28 日),通过 2021 年 5 月 21 日的监测。
筛查效果、风险分层和替代筛查方法的准确性、检测准确性以及筛查危害的随机临床试验和观察性研究。
一名调查员提取数据;第二名调查员检查准确性。两名调查员独立评估研究质量。
感染并发症;感染传播或获得;解剖部位特异性检测和采集方法的诊断准确性;筛查危害。
纳入了 27 项研究(N=179515)。与不筛查相比,4 项试验中有 2 项试验显示衣原体筛查与盆腔炎(PID)风险降低显著相关,且与医院诊断 PID(0.24%比 0.38%)降低相关;相对风险,0.6 [95%CI,0.4-1.0]),但在最大的试验中,与诊所诊断 PID 或附睾炎无关。在无症状女性风险预测工具的研究中,年龄小于 22 岁与广泛标准的准确性相当。在女性的宫颈(89%-100%)和自我及临床医生收集的阴道(90%-100%)部位以及男性的尿道(100%)、尿道(99%)和直肠(92%)部位,衣原体检测的敏感性相似,但在男男性行为者的咽部位(69.2%)较低。在所有解剖部位的检测中,淋球菌检测的敏感性均为 89%或更高。在所有解剖部位和采集方法中,假阳性和假阴性检测率均较低。
衣原体感染筛查与年轻女性 PID 风险降低显著相关。风险预测标准除了年龄之外,准确性有限。对无症状的衣原体和淋病感染进行检测,在大多数解剖部位,包括尿液和自我采集标本,均具有高度准确性。男性和孕妇筛查的有效性、最佳筛查间隔以及筛查的不良影响仍需进一步评估。